MIT researchers suggests a potential molecular strategy for treating fragile X syndrome by enhancing NMDA subunit function.
Immune cell populations of people with post-vaccination syndrome had lower levels of effector CD4 T cells and higher levels ...
Lyric Mariah Heard spoke with "Good Morning America" about her life as a model born with a rare birth defect and using humor ...
Building on more than two decades of research, a study by MIT neuroscientists at The Picower Institute for Learning and Memory reports a new way to treat pathology and symptoms of fragile X syndrome, ...
MIT neuroscientists have made a breakthrough in treating fragile X syndrome by leveraging a novel neurotransmitter signaling ...
Mizuho lowered the firm’s price target on Harmony Biosciences (HRMY) to $42 from $52 and keeps an Outperform rating on the shares. The firm ...
The U.S. Food and Drug Administration has approved a new drug application for a tablet version of Evrysdi (risdiplam) for ...
According to new research announced today, the fragile X syndrome (FXS) market across the USA and Germany is projected to ...
A growth occurring in the next five years will be fuelled by the launch of two high-priced pipeline products providing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback